Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Design, synthesis, and biological evaluation of 2-morpholino-4H-chromen-4-one derivatives as a potent dual PI3K/BRD4 inhibitors.

European journal of medicinal chemistry·2026
Same author

Development and Validation of an LC-MS/MS Method for the Quantitation of JNJ-64619178 (JNJ) in Mouse Plasma: Characterization of In Vitro and In Vivo Pharmacokinetic Properties.

Molecules (Basel, Switzerland)·2026
Same author

Tumor Lipidomic Changes after Treatment with Polymeric Hydroxychloroquine in a Syngeneic Murine Model of Pancreatic Cancer.

ACS omega·2026
Same author

Reactive Oxygen Species-Responsive Polymeric Chloroquine Nanogel for Targeted Oral Therapy of Ulcerative Colitis.

ACS applied materials & interfaces·2025
Same author

Crossing the Blood-Brain Barrier: Innovations in Receptor- and Transporter-Mediated Transcytosis Strategies.

Pharmaceutics·2025
Same author

<i>TP53</i> upregulation via aurora kinase inhibition overcomes primary failure to venetoclax in <i>BCL2-</i>rearranged lymphomas.

iScience·2025

Related Experiment Video

Updated: Jan 12, 2026

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.2K

Discovery of a "First-in-Class" Selective Multikinase (CDK4/6/9-AURKA/B) Inhibitor, LCI133, for Neuroblastoma.

Krishnaiah Maddeboina1,2, Dhananjaya Pal1, Bharath Yada1

  • 1Atrium Health Wake Forest Baptist Comprehensive Cancer Center/Levine Cancer Institute, Charlotte, North Carolina 28204, United States.

Journal of Medicinal Chemistry
|November 6, 2025
PubMed
Summary

A novel multi-target inhibitor, LCI133, shows promise for high-risk cancers by targeting multiple kinases. This approach may overcome resistance and improve safety and efficacy in neuroblastoma treatment.

More Related Videos

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.2K
Real-Time Monitoring of Aurora kinase A Activation using Conformational FRET Biosensors in Live Cells
06:29

Real-Time Monitoring of Aurora kinase A Activation using Conformational FRET Biosensors in Live Cells

Published on: July 30, 2020

3.4K

Related Experiment Videos

Last Updated: Jan 12, 2026

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.2K
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.2K
Real-Time Monitoring of Aurora kinase A Activation using Conformational FRET Biosensors in Live Cells
06:29

Real-Time Monitoring of Aurora kinase A Activation using Conformational FRET Biosensors in Live Cells

Published on: July 30, 2020

3.4K

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • High-risk cancers often develop resistance to single-target therapies.
  • Developing multi-target inhibitors offers a strategy to overcome therapeutic resistance.

Purpose of the Study:

  • To discover and characterize a novel small molecule inhibitor targeting multiple kinases.
  • To evaluate the safety and efficacy of this inhibitor in preclinical models of neuroblastoma.

Main Methods:

  • Rational pharmacophore merging and X-ray crystallography were used to design LCI133.
  • Kinome profiling (scanMAX assay) assessed LCI133 selectivity against 468 kinases.
  • Pharmacokinetic studies in mice and in vitro/in vivo efficacy studies in neuroblastoma models were performed.

Main Results:

  • LCI133 is a potent nanomolar inhibitor of CDK4/6/9 and AURKA/B, with high selectivity.
  • Pharmacokinetic studies showed good systemic exposure in mice (AUC: 7812 ng × h/mL, Cmax: 3305 ng/mL).
  • LCI133 demonstrated nanomolar sensitivity in neuroblastoma cells and potent antitumor effects in vivo without overt toxicity, improving survival rates.

Conclusions:

  • LCI133 represents a first-in-class multi-target inhibitor with potential for treating high-risk cancers like neuroblastoma.
  • The multi-targeting strategy may offer improved safety and efficacy by circumventing resistance mechanisms.